Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;57(2):253-262.
doi: 10.5946/ce.2022.216. Epub 2023 May 16.

Risk factors for recurrent stenosis after balloon dilation for benign hepaticojejunostomy anastomotic stricture

Affiliations

Risk factors for recurrent stenosis after balloon dilation for benign hepaticojejunostomy anastomotic stricture

Takafumi Mie et al. Clin Endosc. 2024 Mar.

Abstract

Background/aims: Hepaticojejunostomy anastomotic stricture (HJAS) is a feared adverse event associated with hepatopancreatobiliary surgery. Although balloon dilation for benign HJAS during endoscopic retrograde cholangiopancreatography with balloon-assisted enteroscopy has been reported to be useful, the treatment strategy remains controversial. Therefore, we evaluated the outcomes and risk factors of recurrent stenosis after balloon dilation alone for benign HJAS.

Methods: We retrospectively analyzed consecutive patients who underwent balloon-assisted enteroscopy-endoscopic retrograde cholangiopancreatography for benign HJAS at our institution between July 2014 and December 2020.

Results: Forty-six patients were included, 16 of whom had recurrent HJAS after balloon dilation. The patency rates at 1 and 2 years after balloon dilation were 76.8% and 64.2%, respectively. Presence of a residual balloon notch during balloon dilation was an independent predictor of recurrence (hazard ratio, 2.80; 95% confidence interval, 1.01-7.78; p=0.048), whereas HJAS within postoperative 1 year tended to be associated with recurrence (hazard ratio, 2.43; 95% confidence interval, 0.85-6.89; p=0.096). The patency rates in patients without a residual balloon notch were 82.1% and 73.1% after 1 and 2 years, respectively.

Conclusion: Balloon dilation alone may be a viable option for patients with benign HJAS without residual balloon notches on fluoroscopy.

Keywords: Adverse events; Balloon dilation; Balloon-assisted enteroscopy; Endoscopic retrograde cholangiopancreatography; Hepaticojejunostomy anastomotic stricture.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no potential conflicts of interest.

Figures

Fig. 1.
Fig. 1.
Balloon dilation on fluoroscopy. (A) No balloon notch. (B) Residual balloon notch (arrow).
Fig. 2.
Fig. 2.
Patient flow chart. BAE, balloon-assisted enteroscopy; ERCP, endoscopic retrograde cholangiopancreatography; HJAS, hepaticojejunostomy anastomosis stricture; EUS-BD, endoscopic ultrasound-guided biliary drainage; PTBD, percutaneous transhepatic biliary drainage.
Fig. 3.
Fig. 3.
Time to recurrent stenosis after first balloon dilation for HJAS. HJAS, hepaticojejunostomy anastomosis stricture; NA, not available; CI, confidence interval.
Fig. 4.
Fig. 4.
Time to recurrent HJAS based on presence of residual balloon notch. HJAS, hepaticojejunostomy anastomosis stricture; NA, not available; CI, confidence interval.
None

Similar articles

Cited by

References

    1. House MG, Cameron JL, Schulick RD, et al. Incidence and outcome of biliary strictures after pancreaticoduodenectomy. Ann Surg. 2006;243:571–578. - PMC - PubMed
    1. Reid-Lombardo KM, Ramos-De la Medina A, Thomsen K, et al. Long-term anastomotic complications after pancreaticoduodenectomy for benign diseases. J Gastrointest Surg. 2007;11:1704–1711. - PubMed
    1. Dimou FM, Adhikari D, Mehta HB, et al. Incidence of hepaticojejunostomy stricture after hepaticojejunostomy. Surgery. 2016;160:691–698. - PMC - PubMed
    1. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–673. - PubMed
    1. Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Lancet. 2016;388:248–257. - PubMed

LinkOut - more resources